Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influences

Patent metadata

Field	Value
Publication number	US-2021002725-A1
Application number	US-202016805557-A
Country	US
Kind code	A1
Filing date	Feb 28, 2020
Priority date	May 11, 2009
Publication date	Jan 7, 2021
Grant date	—

Abstract

Methods and formulations for diagnosing metabolic disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.

First claim

1 . A method of identifying a subject afflicted with a metabolic disorder in a Coenzyme Q10 responsive state, the method comprising:
(1) detecting the level of expression of at least one marker present in a biological sample obtained from a subject having a metabolic disorder, wherein the at least one marker comprises one or more marker proteins listed in Tables 2-4, 6-29 and 64-69 wherein the subject has been administered Coenzyme Q10; and (2) comparing the level of expression of the at least one marker in the biological sample to the level of expression of the at least one marker present in a control sample, wherein the control sample is a biological sample obtained from the subject prior to administration of Coenzyme Q10, wherein the subject is determined to be afflicted with a metabolic disorder in a Coenzyme Q10 responsive state when the level of expression of the at least one marker in the biological sample is modulated relative to the level of expression of the at least one marker in the control sample.

2 - 10 . (canceled)

11 . The method of claim 1 , wherein the metabolic disorder is a disorder selected from the group consisting of diabetes, obesity, pre-diabetes, hypertension, cardiovascular disease, metabolic syndrome, and any key elements of a metabolic disorder.

12 . (canceled)

13 . The method of claim 1 , wherein the sample comprises a fluid obtained from the subject.

14 . The method of claim 13 , wherein the fluid is selected from the group consisting of blood fluids, vomit, saliva, lymph, and urine.

15 . The method of claim 14 , wherein the sample is a blood sample or a component thereof.

16 - 17 . (canceled)

18 . The method of claim 1 , wherein the subject is a human.

19 . The method of claim 1 , wherein the level of expression of the at least one marker in the biological sample is determined by assaying a transcribed polynucleotide or a portion thereof in the sample.

20 . The method of claim 19 , wherein assaying the transcribed polynucleotide comprises amplifying the transcribed polynucleotide.

21 . The method of claim 1 , wherein the level of expression of the at least one marker in the subject sample is determined by assaying a protein or a portion thereof in the sample.

22 . The method of claim 1 , wherein the at least one marker is assayed using a detection reagent which specifically binds the marker.

23 . (canceled)

24 . The method of claim 22 , wherein the detection reagent is selected from the group consisting of an antibody and an antigen-binding antibody fragment.

25 . The method of claim 1 , wherein the level of expression of the at least one marker in the sample is determined using a technique selected from the group consisting of polymerase chain reaction (PCR) amplification reaction, reverse-transcriptase PCR analysis, single-strand conformation polymorphism analysis (SSCP), mismatch cleavage detection, heteroduplex analysis, Southern blot analysis, Northern blot analysis, in situ hybridization, array analysis, deoxyribonucleic acid sequencing, restriction fragment length polymorphism analysis, and combinations or sub-combinations thereof, of said sample.

26 . The method of claim 1 , wherein the level of expression of the at least one marker in the sample is determined using a technique selected from the group consisting of immunohistochemistry, immunocytochemistry, flow cytometry, Western blot analysis, ELISA and mass spectrometry.

27 - 34 . (canceled)

35 . The method of claim 1 , wherein the at least one marker comprises two, three, four, five, ten, twenty, thirty, forty or fifty of the marker proteins listed in Tables 2-4, 6-29 and 64-69.

36 - 55 . (canceled)

56 . The method of claim 1 , further comprising continuing administration of Coenzyme Q10 to a subject determined to be afflicted with a metabolic disorder in a Coenzyme Q10 responsive state.

Assignees

• Berg Llc

Inventors

• Narain Niven Rajin
• Mccook John Patrick
• Sarangarajan Rangaprasad

Classifications

• G01N33/5758 Primary

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• A61K31/00 Primary

  Medicinal preparations containing organic active ingredients · CPC title

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• C12Q2600/16

  Primer sets for multiplex assays · CPC title

• A61P13/12

  of the kidneys · CPC title